US Stock Insider Trading | Nuvalent disclosed 8 insider transactions on March 2

2026-03-10 23:23:18

Abstract generation in progress

On March 2, 2026, Nuvalent (NUVL) disclosed eight insider trading transactions. Executive Noci Darlene purchased 5,500 shares on February 26, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Executive	Miller Deborah Ann	February 26, 2026	Buy	5,500	6.89	$38,900
March 2, 2026	Executive	Miller Deborah Ann	February 26, 2026	Sell	200	103.96	$2,079
March 2, 2026	Executive	Noci Darlene	February 26, 2026	Sell	2,300	103.44	$237,900
March 2, 2026	Executive	Noci Darlene	February 26, 2026	Sell	200	104.25	$2,085
March 2, 2026	Executive	Miller Deborah Ann	February 26, 2026	Sell	2,698	102.64	$276,800
March 2, 2026	Executive	Miller Deborah Ann	February 26, 2026	Sell	2,602	103.41	$268,100
March 2, 2026	Executive	Noci Darlene	February 26, 2026	Sell	3,000	102.64	$308,400
March 2, 2026	Executive	Noci Darlene	February 26, 2026	Buy	5,500	27.85	$153,175
February 2, 2026	Executive	Noci Darlene	January 29, 2026	Sell	1,819	102.67	$186,800
February 2, 2026	Executive	Noci Darlene	January 29, 2026	Sell	3,429	101.80	$348,900

[Company Information]

Nuvalent, Inc. was incorporated on January 25, 2017, under Delaware law. The company is a clinical-stage biopharmaceutical company focused on creating precision targeted therapies for cancer patients. Leveraging the team’s deep expertise in chemistry and structure-based drug design, the company develops innovative small molecules aimed at overcoming limitations of existing therapies targeting clinically validated kinase targets. Current kinase inhibitors face potential limitations such as (i) kinase resistance or mutations that confer resistance to existing therapies, (ii) kinase selectivity issues where current therapies may inhibit structurally similar kinases leading to off-target adverse events, and (iii) limited blood-brain barrier penetration, affecting the ability to treat diseases that have spread or metastasized to the brain.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes